Re: Trial

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Trial

in response to

Re: Trial

Hartland

posted on Sep 07, 2016 11:48AM

I really have no idea how many patients are in the trial right now. I was only extrapolating from my understanding of the 3 + 3 dose escalation design. But if those assumptions are correct, then yes the 4th cycle will allow for 12 patients. Whenever Zenith provides a Q3 update (hopefully) or the AGM (not currently scheduled), hopefully we get some clarity on this.